Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue SarcomaYasuyoshi Sato, Shunji Takahashi, Masanori Saito et al.|Cancers|2021Cited by 12
Changes in Neutrophil-to-lymphocyte Ratio Predict Efficacy of Trabectedin for Soft-tissue SarcomaYasuyoshi Sato, Shunji Takahashi, Kenji Nakano et al.|Cancer Diagnosis & Prognosis|2021Cited by 5
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective studyAkihiro Ohmoto, Shunji Takahashi, Kenji Nakano et al.|PLoS ONE|2023Cited by 3
Post-Systemic Chemotherapy Prognoses of Recurrent/Metastatic Soft Tissue Sarcoma Patients with Retroperitoneal/Intra-Abdominal Origin versus Those with Extremities/Trunk OriginKenji Nakano, Shunji Takahashi, Naoki Fukuda et al.|Oncology|2022Cited by 0
Gemcitabine-Based Chemotherapy for Advanced Soft Tissue Sarcoma: Identifying the Appropriate Dose and ScheduleKenji Nakano, Shunji Takahashi, Naomi Hayashi et al.|Cureus|2024Cited by 0